Skip to main content
. 2018 Jul 6;2(13):1572–1579. doi: 10.1182/bloodadvances.2018017772

Figure 3.

Figure 3.

TL of 134 CML patients within the EURO-SKI study. (A) TL (in kb) vs age (in years) in PB lymphocytes of CML patients with loss of (orange squares; n = 58) or maintained (blue circles; n = 75) molecular residual disease. (B) TL (in kb) vs age (in years) in PB granulocytes of CML patients with loss of (green squares; n = 58) or maintained (yellow circles; n = 75) molecular residual disease. (C) Age-adjusted TL (aaTL) of PB lymphocytes (shown in blue; P = .020) and granulocytes (shown in yellow; P = .100) from the EURO-SKI study patients. n.s., not significant.